Hydrogel rectum-prostate spacers and anterior-oblique proton beams ”

Introduction: Anterior-oblique (AO) proton beams form an attractive option for prostate patients receiving external beam radiotherapy (EBRT) as they avoid the femoral heads. For a cohort with hydrogel prostate-rectum spacers, we asked whether it was possible to generate AO proton plans robust to end-of-range elevations in linear energy transfer (LET) and modelled relative biological effectiveness (RBE). Additionally we considered how rectal spacers influenced planned dose distributions for AO and standard bi-lateral (SB) proton beams versus intensity-modulated radiotherapy (IMRT). Material and methods: We studied three treatment strategies for ten patients with rectal spacers: (A) AO proton beams, (B) SB proton beams and (C) IMRT. For strategy (A) dose and LET distributions were simulated (using the TOPAS Monte Carlo platform) and the McNamara model was used to calculate proton RBE as a function of LET, dose per fraction, and photon α/β. All calculations were performed on pre-treatment scans: interand intrafractional changes in anatomy/set-up were not considered. Results: For 9/10 patients, rectal spacers enabled generation of AO proton plans robust to modelled RBE elevations: rectal dose constraints were fulfilled even when the variable RBE model was applied with a conservative α/β=2Gy. Amongst a subset of patients the proton rectal doses for the PTV plans were remarkably low: for 2/10 SB plans and 4/10 AO plans, ≤10% of the rectum received ≥20 Gy. AO proton plans delivered integral doses a factor of ~3 lower than IMRT and spared the femoral heads almost entirely. Conclusion: Typically, rectal spacers enabled the generation of anterior beam proton plans that appeared robust to modelled variation in RBE. However, further analysis of day-to-day robustness would be required prior to a clinical implementation of AO proton beams. Such beams offer almost complete femoral head sparing, but their broader value relative to IMRT and SB protons remains unclear.

[1]  D. Low,et al.  Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Annie Gao,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.

[3]  Y. Lotan,et al.  Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. , 2016, Urologic oncology.

[4]  K. Herfarth,et al.  Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial. , 2016, International journal of radiation oncology, biology, physics.

[5]  Harald Paganetti,et al.  Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[6]  H. Katoh,et al.  Changes in Rectal Dose Due to Alterations in Beam Angles for Setup Uncertainty and Range Uncertainty in Carbon-Ion Radiotherapy for Prostate Cancer , 2016, PloS one.

[7]  K. Parodi,et al.  Clinical commissioning of an in vivo range verification system for prostate cancer treatment with anterior and anterior oblique proton beams , 2015, Physics in medicine and biology.

[8]  V. Heikkilä PEG spacer gel and adaptive planning vs single plan in external prostate radiotherapy--clinical dosimetry evaluation. , 2015, The British journal of radiology.

[9]  J. Deasy,et al.  Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer , 2015, Acta oncologica.

[10]  L. Muren,et al.  A method for evaluation of proton plan robustness towards inter-fractional motion applied to pelvic lymph node irradiation , 2015, Acta oncologica.

[11]  H. Woo,et al.  Rectal ulcer associated with SpaceOAR hydrogel insertion during prostate brachytherapy , 2014, BMJ Case Reports.

[12]  C. Deville,et al.  Effect of intrafraction prostate motion on proton pencil beam scanning delivery: a quantitative assessment. , 2013, International journal of radiation oncology, biology, physics.

[13]  M. Santoro,et al.  Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years , 2013, Radiation oncology.

[14]  H Paganetti,et al.  TOPAS: an innovative proton Monte Carlo platform for research and clinical applications. , 2012, Medical physics.

[15]  I. Toma-Dasu,et al.  Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients , 2012, Acta oncologica.

[16]  C. King,et al.  Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes , 2011, Radiation oncology.

[17]  C. Lawton Radiation dose–volume effects of the urinary bladder , 2011 .

[18]  J. Deasy,et al.  Radiation dose-volume effects in radiation-induced rectal injury. , 2010, International journal of radiation oncology, biology, physics.

[19]  Alexei Trofimov,et al.  Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. , 2007, International journal of radiation oncology, biology, physics.

[20]  Rick Chappell,et al.  Is α/β for prostate tumors really low? , 2001 .

[21]  D J Brenner,et al.  Fractionation and protraction for radiotherapy of prostate carcinoma. , 1999, International journal of radiation oncology, biology, physics.